




Not developing biotechnology would be a greater risk
than developing it
My opinions on biotech and of what is happening in Europe are from a general
industrial perspective rather than from Nestlé’s perspective in particular. To
avoid any misunderstanding, the Nestlé corporate position on biotechnology is
very clear: we believe that we need to develop and use it, and we will support it
wherever and whenever we can. Only a few days ago, our CEO in Switzerland
said that not developing biotechnology would be a greater risk than developing
it. That is an unmistakable position, but we have to realize that we operate in
the real world, and sometimes there are things that you want to do but cannot.
I gave a presentation on this subject here in the United States about a year
and a half ago, and, in response, people saw me as a doomsayer, out of touch
with reality. It is rather unfortunate, but the situation today is no more rosy
than I pictured it then; if anything, it is probably worse than I predicted it
would be. Take, for example, the shift in European soybean imports from
the United States to Brazil. We believe that a major motive was that Brazil
positioned itself as a “non-GM” country. Four million tons that previously came
from United States now come from Brazil. Apparently, no one was hurt by that
move, because global trade increased enormously with China. What could not
be sold to Europe is being sold to China. Ironically, the Chinese use that
genetically modified soy to grow chickens that are exported to Europe.
LABELING
About twenty countries in the world now either have labeling regulations or are
considering them. They are all different. The following is a short, perhaps
imprecise, summary. One country has enacted a complete ban: Sri Lanka
banned all GM ingredients as of May 1, 2001. We have been in discussion with
Saudi Arabia for some time, because they are considering a ban. Their very
restrictive labeling legislation will come into effect in November, 2001.
Obviously, this is a significant barrier to trade. If you have centralized
production and want to export to those countries, you face problems similar to
those of about 20 or 25 years ago with additives and other ingredients.
PERSPECTIVE
I will spend a little time on how we got to this point, just a few remarks. We
have seen food scares and mounting public distrust. Opinion polls on
biotechnology in Europe, showed an across-the-board decrease of 10% in public
acceptance between 1996 and 2000. This was not limited to agriculture and
food, it included pharmaceuticals. More striking was that it focused on moral or
ethical aspects of acceptability. Opinions being formed at the moment are not
very positive. Uncertainty was at the root of the problem. When GM products
came to the market in Europe, we were faced with contradictory statements or
even silence both from regulators and from industry. This contributed
substantially to the lack of confidence now prevalent.
European culture, food culture, and agriculture have been mentioned at this
meeting. It would not be so bad if we Europeans were more modest. European
food culture is extremely important, but, on the other side of coin, are the food
scandals and scares of the past ten years, such as BSE and foot and mouth
disease.
A little modesty would also help with European agriculture. I have the
impression, when talking to Europeans –– it does not matter which member
state you are in –– that farming is seen as part of the fabric of daily life. I
commute seven minutes from my home to work and pass many farms, with
sheep, horses, cows, grapes, corn, wheat, and potatoes. There is a feeling that
European agriculture is purer and much closer to nature compared to industrial
agriculture in the United States. Yet, if you look at data that are available on
various web-sites, you will find that use of chemicals in Europe is much higher
than it is in America. When I use this argument in Europe, they are not pleased
to hear it. But, it is a fact. Therefore, more modesty would be beneficial.
POSITIVE DEVELOPMENTS
So far, it has been all gloom and doom. Let us consider positive developments,
because there definitely have been some. It looks as if the ban on thinking and
speaking about biotech has been broken! For years politicians did not dare
speak out on this subject, or they were very secretive. People who were
supportive dared to say so only in closed meetings far away from publicity. That
has changed. The European Parliament recently published a report on the
future of biotechnology in Europe. There is a strong emphasis on pharmaceuti-
cal biotechnology and applications in the medical sector, but attention is given
also to applications in the agri-food sector with a strong encouragement to look
at it, to work on it, and to take what is applicable in a European situation. The
same is true of an opinion drafted by Mikko Pesälä, a Finnish member of the
European Parliament, which focuses on agriculture applications and is positive
regarding environmental benefits in the short term and food-quality advantages
in the longer term.
In the European Commission there is great deal of activity. Several commis-
sioners are involved in getting biotechnology going again; one group is headed
by the Commission President, Romano Prodi himself. Sound regulation that
will authorize the possibility to grow genetically modified crops has finally been
adopted. Currently under discussion is the framework for research, which is
focusing on genomics and genetics.
The European Council, which consists of representatives of the European
member states, convened in Stockholm and made very clear statements on the
advantages of biotechnology, focusing mainly on pharmaceuticals, but
including agricultural and food applications.
These are all positive elements; however, quite a few “buts” remain. The
moratorium continues. Six member states have indicated that they will stop the
moratorium only when traceability labeling and liability are regulated. The new
proposals from the commission may or may not satisfy demands from those six
member states, from activist organizations, from consumers, and from the
biotech industry. There is fear that this collection of new proposals may
overshoot the target because it is focusing completely on GMOs and includes
fundamental change in certain policies.
SEED TO FATE
What are the major changes? The framework goes further than “seed to plate”;
it covers release into the environment including seed thresholds, traceability,
labeling of food and feed, and monitoring and post-marketing of the final
product. This is “seed to fate” rather than “seed to plate.” The food industry is
concerned that the focus is on GMOs, as if they have become the scapegoat for
everything wrong in our legislation, and in our European food culture and
agriculture: thus, in bearing responsibility for all of these sins, biotechnology
will be sacrificed. Singling out biotech will have a negative effect on the public.
We do not have to look far to see that other problems are related to our agri-
food chain.
What will change? First of all there is traceability, which is often confused
with identity preservation. Traceability depends on the informatics, the
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infrastructure of a country, and it already exists. Normally when you buy an
ingredient, you know from whom you are buying and you know what you are
buying. The producer of the ingredient knows from whom he is buying, and so
on and so forth. There is a requirement in hygiene legislation and there will be
a requirement in the new European food law for all of the players to preserve
that information and to make it available. However, at this time, a gap exists
and the gap is feed, and we think that that gap should be filled because many of
our problems have originated from that sector.
So, traceability should be extended to the full chain for reasons of safety and
quality. It is not information that is usually communicated—it is not informa-
tion that is transported along the chain. There is no master dossier that goes
with each ingredient to the end-producer. Some of the systems now in place are
such that we can trace back to a certain time, say between 12:43 and 12:57, for
a specific problem (of course not all parts of the chain are so precise).
Identity preservation is entirely different. To give you one example: yogurt
made with apples or pears from Anjou is marketed in France. For a certain
period of time, the yogurt is made using only those fruits. There you have a
system with identity preservation, meaning that you go to the supplier, tell
them what you want and get the information, which travels along the chain and
is communicated to the consumer, and, eventually, that yogurt will be 10, 15, or
20% more expensive. In the discussions on-going in Brussels, this identity-
preservation idea, where you limit your purchasing flexibility, where you
increase costs, where you increase the amount of data and information to be
managed, is seen as traceability and is explained as traceability. But I see it as
being at odds with the concept of traceability.
The next aspect, labeling, has seen an important change. In the EU, as of
mid-1999, we had to label all ingredients that were derived from raw materials
with a GMO content of more than 1% based on DNA. Proteins also were
mentioned, but no analytical methods are available. If you are below that 1%
and have documentation to prove efforts to separate or segregate, labeling is not
needed. If the ingredient is negative by PCR, you do not have to label. These are
the three criteria for current European legislation. Along with other food
producers, we at Nestlé introduced labeled products to the market that came
heavily under fire and were removed from the shelves by the supermarkets.
Genetically modified ingredients were slowly phased out, and, by and large, the
European market no longer uses GM ingredients.
We saw a rapid decrease in consumer calls. In 1999, Nestlé France received
more than 15,000 phone calls on GM: Are you using GMOs? What is it? Are
they safe? Can you guarantee that it’s not in there? etc. Labeling regulations
brought clarity about what was happening, and we stopped receiving consumer
calls on GM. In 2000, we had about 1,500 calls referring to GM, but they were
all triggered by concern over BSE. From our perspective, calm had returned and
consumers were reasonably happy with the situation.
However, Europe is not GM free. In Switzerland checks are made regularly
by local inspectors who usually find that 10 to 20% of samples are positive,
but well below the threshold of 1%. So, although Europe is non-GM, it is not
GM-free.
THE FUTURE
If I understand the proposals correctly––I saw the first draft only a week and
half ago––then detectability, as a criterion, has disappeared. There is a move to
process labeling, meaning that even if an ingredient is negative by PCR and you
do not have documentation, you must label. It includes food ingredients,
additives, and flavorings. As I see it, we are moving from practical labeling,
based on facts, to ethical labeling. Practical labeling indicates when GM
ingredients are present. If GM ingredients are not detectable, then the product
is not labeled; however, realizing that the world is not an ideal place, a GM
ingredient may be present—below a certain threshold—that you wish to avoid.
With ethical labeling, the use of biotechnology anywhere in the process must be
indicated on the label. This different proposition exists already, but only for
some niche markets. Many people offer “organic” as an example of it, which is
not entirely true since organic has a 5% tolerance. Ethical, or process, labeling
is an entirely different approach from practical labeling, in my view.
We are concerned about the enforceability of this legislation. If there no
longer is detectibility then reliance on a paper trail is necessary and we are
afraid that, in practice, for highly processed products containing large numbers
of ingredients, enforcement will be difficult.
It looks as if products that have already been authorized will have to be
reauthorized within a period of four years after the law is enacted. I do not
understand why. It may be that concerns remain about safety or that we want to
adopt a ten-year limit also on those products.
The other new element is post-market monitoring or surveillance. I have had
a number of very confusing discussions on post-market surveillance. A few
weeks ago, a group of eminent European scientists, food-safety experts, and
molecular biologists, gathered in an EC research center in Italy. I was there
as a representative of the food industry. Consumers were represented also.
Discussion ensued on the safety of “one-gene” products currently on the
market and those expected in the next five to ten years. Within a few hours
Checks are made regularly by local inspectors who
usually find that 10 to 20% of samples are positive,
but well below the threshold of 1%. So, although Europe
is non-GM, it is not GM-free.
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there was agreement that these do not constitute a serious safety issue. We have
the tools, we have the people, and we have the equipment to come to consistent
conclusions about safety. But when discussing more complicated products, the
group felt that reviews of equipment and available tools would be needed, to
verify safety. Some people said that there is a need to look for unknown long-
term effects of ingredients and components that come from the consumption of
GM raw materials in the long term. This confuses me. I can imagine that you
would have post-market monitoring if you have a product that is said to have a
certain effects, such as decreasing blood pressure or reducing cholesterol. If you
want to monitor those effects, you can devise tools accordingly. A product
might have a negative side effect that you would want to monitor in a certain
sensitive group, although I have difficulty envisaging a company marketing
such an item. If the idea behind post-market surveillance is that the product
might not be safe, then, in my opinion, it should not be on the market. If you
have post-market surveillance for safety reasons, you might also ask, why do we
have food-safety authorities? I do not believe that any responsible company
would bring a food product to market if it was to be monitored for general
safety reasons. Certainly it would not be done in the United States, where
liability is commonly an issue. I would be happy to discover that I misunder-
stand the intent here, because this development seems dangerous.
What will be the effect of this package? If all goes well, if questions are
resolved about traceability, about labeling, and about liability, we may see
approvals of GM crops. But if labeling will be extended to virtually every
product, given the current situation, it will result in increased demands for non-
GM foods. I believe the European market will follow the clean-label policy in
the current climate. We will also see increased pressure on GM animal feed and
derived animal products. The moment you have an ethical basis for labeling, it
is very difficult to keep it contained to the original intent because there seldom
exists a good argument not to extend it to other areas.
The situation regarding processing and use of components such as enzymes
is also unclear. Currently they are not within the scope of the legislation, but
we do not know how this will evolve. We see world-trade implications as major
issues for the future that may involve the WTO. Importation of a composite
product is going to be extremely difficult to monitor and control. Enforcement
is going to be extremely difficult also. Availability of ingredients may become an
issue. And finally, formulating legislation on the premise that GM is fundamen-
tally dangerous engenders public concern. Therefore, I am afraid that safety will
re-enter the general discussion.
Q: Having looked a lot at nutrition surveys, the thing I don’t understand is
how do people imagine you can do a post-market surveillance? How would you
recognize a cause-and-effect relationship in the complexity of the human diet,
considering the small amount of any one particular product that people eat?
A: Frankly, I haven’t a clue. There is a system that involves physicians. It
differs with each member states, but if there is a persistent pattern of problems,
then at a certain point, after having passed a number of hurdles, it goes into the
health system and, based on epidemiological studies, a link may be found.
Certain cases are known over the past twenty years even, where this has
happened. Based on clusters of symptoms, the system reacts. But it is largely
passive, and I fail to see how it could be made active when the symptoms are
unknown at the outset.
Q: About labeling: if it does go into effect as you suggest, wouldn’t almost
everything get the “GM” label and then the stigma would be lost?
A: It is true that if you do have massive labeling, it’s over. If everybody would
label there would no longer be a problem. First of all you could question the
value of having massive labeling. Secondly, we saw with the labeling exercise we
went through in the late 1990s, that despite all of the agreements, all sorts of
people wiggled out. You get a very disturbed market and a situation that is very
difficult to handle.
Q: Along those lines, what kind of label were people responding to? Was it a
big label on the front of the package? Was there any law on how you had to
display the fact that there was a GMO in there?
A: The labeling in Europe is quite clear. If you have a soy protein, then
immediately following the soy protein name on the label it must be stated that
it comes from genetically modified soya, or you can do it with an asterisk if
there are other ingredients. The asterisk indicates that it contains GM soya. We
should not forget one thing, however that the initial introduction provoked no
reaction whatsoever from the public. Only after activists discovered long-term
food safety in the supermarket as their battlefield, did problems arise.
Q: Will any food processor in Europe ever market a product containing
GMOs, given these conditions?
A: That depends on the product. There are practical considerations why you
would not use GM ingredients. You do not offer the consumer a choice of two
similar products if the GM ingredient is not characteristic or critical; you look
for the simple solution. Where you have an ingredient that is characteristic for
the product, an ingredient to which the consumer attaches value, then you offer
the choice. I am not saying that you will never see any GM product in Europe.
We will go through a prolonged difficult period during which we will see
avoidance efforts. But, the moment something appears that is attractive or the
moment somebody comes to the conclusion that it will be better for the
environment to use GM crops in Europe, and that idea is sold, there will be a
turn-around.
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Q: It seems rather amazing to many of us in the United States that a process
label could be put in place––an ethical label could be put in place. How can you
limit then what goes on to a label if people are concerned about pesticide use, if
people are concerned about what ethnic group produced their food, etc.?
A: That’s a question mark.
